文献速递急性肾损伤遗传性与小管间质肾病

EXOSC3双等位基因致病突变介导肾脏血栓性微血管病

Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney.
PubMed 文献 · Kidney Int · 2026-07-22

Exosc3条件敲除小鼠出现细胞周期阻滞和凋亡,中位8天死亡,但该时间内未发现肾脏病理。结论认为EXOSC3-TMA是早发、严重且对C5抑制剂抵抗的TMA。

要点

  • EXOSC3-TMA是早发、严重且对依库珠单抗抵抗的TMA。
  • 依库珠单抗抵抗的儿童TMA,尤其伴神经发育疾病时,应想到EXOSC3-TMA。
  • EXOSC3-TMA与PCH1b相关,英国发病率0.004/百万/年。

核心结论

  • EXOSC3-TMA是一种严重、早发且对C5抑制剂抵抗的TMA。
  • 对依库珠单抗抵抗的儿童TMA,尤其合并神经发育疾病时,应考虑EXOSC3-TMA。

研究设计与样本

  • 研究纳入欧洲34例因EXOSC3罕见变异导致PCH1b的儿童,回顾性审查TMA临床征象。
  • 使用他莫昔芬诱导的全身性Exosc3条件敲除小鼠模型(Exosc3KO)探究发病机制。

主要发现

  • 英国EXOSC3-TMA发病率为0.004/百万/年。
  • 3例患儿接受长期依库珠单抗治疗:1例无应答,2例治疗中复发。
  • Exosc3KO小鼠出现细胞周期阻滞和凋亡,中位8天死亡,骨髓和结直肠活跃分裂细胞出现后遗症;该时间内未发现肾脏病理。

临床怎么用

  • 对依库珠单抗抵抗的儿童TMA,尤其合并神经发育疾病时,应评估EXOSC3基因变异。

局限性

  • Exosc3KO小鼠在观察时间内未发现肾脏病理,机制尚不完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Thrombotic microangiopathy (TMA) is characterized by the classical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Complement inhibition with eculizumab is highly efficacious in TMA secondary to complement dysregulation. However, a growing number of eculizumab-nonresponsive TMAs are reported. Recently, a syndromic form of TMA due to recessive variants in RNA exosome components (EXOSC3 and EXOSC5) has been identified. The underlying pathogenesis remains unclear. METHODS: We identified 34 children across Europe with pontocerebellar hypoplasia 1b (PCH1b) due to EXOSC3 rare variants and reviewed their clinical history for signs of TMA. To further examine the pathogenesis, a tamoxifen-inducible whole-body Exosc3 conditional knockout mouse model (Exosc3KO) was used. RESULTS: Thirteen (eight male, five female) cases of EXOSC3-TMA were identified. In the United Kingdom, the incidence of EXOSC3-TMA was 0.004/million/year. Three children received long-term eculizumab therapy: one child failed to respond and two relapsed on treatment. Exosc3KO demonstrated cell-cycle arrest and apoptosis resulting in death in a median of eight days, with sequelae noted in actively dividing cells in the bone marrow and large intestine. In this timeframe, no kidney pathology was identified. CONCLUSIONS: EXOSC3-TMA is a severe, early-onset, C5 inhibitor-resistant TMA. EXOSC3-TMA should be considered in eculizumab-resistant pediatric TMA, particularly in the context of neurodevelopmental disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Walsh PR, Basu U, Barakat TS, et al. Biallelic pathogenic variants in EXOSC3 mediate thrombotic microangiopathy of the kidney. Kidney Int. 2026. PMID: 42486191. doi:10.1016/j.kint.2026.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。